In 1996, preclinical data demonstrated that a modified 2-phenylaminopyrimidine induced apoptosis of BCR::ABL1-positive human cells, including primary CML cells, with little toxicity to normal cells (Druker et al., 1996). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.